Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Kimberly J. Perez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5745-2994; OpenAlex author ID A5004799675. Sources: ClinicalTrials.gov.

Their work

Papers
34 (first author 3, last author 1)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
159
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper, 2 trials · 2019: 2 papers · 2020: 1 paper, 1 trial · 2021: 5 papers · 2022: 3 papers · 2023: 6 papers, 1 trial · 2024: 2 papers · 2025: 4 papers · 2026: 7 papers

Papers 34

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  4. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  5. Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia. First author DOI 10.21037/jgo-2026-0221↗
  6. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  7. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  8. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  9. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  10. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Last author DOI 10.1200/po-25-00332↗
  11. GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer? First author DOI 10.21037/atm-24-182↗
  12. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  13. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  14. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  15. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  16. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  17. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  18. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  19. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  20. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  21. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  22. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246223↗
  23. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  24. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  25. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. First author DOI 10.1200/jco.21.01510↗
  26. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. Co-author DOI 10.1200/op.20.00678↗
  27. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
  28. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  29. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  30. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  31. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  32. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2016.70.2134↗
  33. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study. Co-author DOI 10.1097/coc.0000000000000246↗
  34. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Co-author DOI 10.2147/ott.s33560↗

Trials 4

  1. A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Principal investigator NCT05546411↗
  2. LY3214996 +/- HCQ in Pancreatic Cancer Principal investigator NCT04386057↗
  3. Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer Principal investigator NCT03316599↗
  4. Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer Principal investigator NCT03520790↗

Closest collaborators

The 25 strongest of 159 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 29 shared papers, 2017–2026 · strength 3.96
  2. Andrew J. Aguirre · 20 shared papers, 2019–2026 · strength 2.85
  3. Harshabad Singh · 17 shared papers, 2021–2026 · strength 2.62
  4. James M. Cleary · 16 shared papers, 2021–2026 · strength 2.31
  5. Jonathan Andrew Nowak · 17 shared papers, 2019–2026 · strength 2.30
  6. Douglas Adam Rubinson · 17 shared papers, 2019–2026 · strength 2.19
  7. Kimmie Ng · 13 shared papers, 2019–2026 · strength 1.60
  8. Rishi Surana · 7 shared papers, 2022–2026 · strength 1.52
  9. Brandon M. Huffman · 9 shared papers, 2022–2026 · strength 1.46
  10. Srivatsan Raghavan · 9 shared papers, 2021–2026 · strength 1.25
  11. Chen Yuan · 11 shared papers, 2019–2024 · strength 1.20
  12. Matthew B.B. Yurgelun · 9 shared papers, 2019–2026 · strength 1.11
  13. Thomas E. Clancy · 9 shared papers, 2017–2026 · strength 1.03
  14. Andressa Dias Costa · 8 shared papers, 2020–2026 · strength 1.03
  15. Joseph Douglas Mancias · 6 shared papers, 2017–2026 · strength 0.84
  16. Stephanie K. Dougan · 5 shared papers, 2022–2026 · strength 0.77
  17. Thomas Adam Abrams · 5 shared papers, 2023–2026 · strength 0.72
  18. Ana Babić · 6 shared papers, 2019–2023 · strength 0.65
  19. Geoffrey Ira Shapiro · 5 shared papers, 2021–2026 · strength 0.64
  20. Steve Gallinger · 4 shared papers, 2022–2026 · strength 0.63
  21. Hannah L. Williams · 5 shared papers, 2021–2025 · strength 0.61
  22. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  23. Edward L. Giovannucci · 5 shared papers, 2019–2023 · strength 0.57
  24. Peter Kraft · 5 shared papers, 2019–2023 · strength 0.57
  25. Vicente Morales‐Oyarvide · 6 shared papers, 2019–2023 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.